Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucinous Oncology and Mucosal Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MUC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MUC2 Truncated ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Ideal for glycan-dependent epitope mapping. |
View MUC2 Products |
| Gene Delivery | MUC2 Promise-ORF / Lentivirus Full-length ORF lentiviral particles for stable cell line construction. Essential for cell-based conformation assays. |
View MUC2 Products |
| Benchmark Ab | Anti-MUC2 Recombinant Antibody Recombinant positive control derived from benchmark research sequences. |
View MUC2 Products |
| Validator | MUC2 siRNA Set For target knockdown verification and specificity validation in vitro. |
View MUC2 Products |
| Related Target A | MUC1 Transmembrane mucin co-expressed in epithelial cancers; critical for off-target and selectivity screening. |
View MUC1 Products |
| Related Target B | MUC16 High-molecular-weight mucin (CA125) mutated or overexpressed in mucinous ovarian cancers. |
View MUC16 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Giant size & complex folding of native MUC2 | Domain-specific truncated recombinant proteins (N-terminal D-domains / C-terminal domain) sequence-verified for structural integrity. |
| Glycosylation-dependent epitope recognition | HEK293 eukaryotic expression host ensures mammalian O-glycosylation patterns, avoiding false negatives in antibody screening. |
| Lack of Standardized Controls | Sequence-defined clinical benchmark antibodies (biosimilars) included for assay calibration. |
| High sequence homology among gel-forming mucins | Cross-reactivity screening panel including MUC5AC and MUC6 recombinant targets to eliminate off-target binding. |
Live MUC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T therapies targeting tumor-specific glyco-epitopes. As first-generation therapies reach the clinic, the next wave of R&D is targeting under-glycosylated MUC2 peptide backbones exposed selectively in mucinous colorectal cancer, pseudomyxoma peritonei (PMP), and gastric carcinomas, minimizing toxicities in healthy secretory tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Biotech Startups, Academic Consortia | Mucinous Colorectal Cancer, Pseudomyxoma Peritonei | Internalization Assay (Requires high-purity, glycosylated ECD-Fc fusion proteins) |
| CAR-T / Cell Therapy | Cell Therapy Specialists | Ovarian Mucinous Carcinoma, Pancreatic Cancer | Conformational Binding Verification (Requires Lentivirus for stable cell line construction) |
| Bispecific Antibodies | Global Biopharma | Solid Tumors (Gastrointestinal) | Selectivity Screening (Requires multi-mucin recombinant target panel) |